Gossamer Bio, Inc.
Status: Publicly traded
Direct answer
Gossamer Bio, Inc. is publicly traded on NASDAQ under the ticker GOSS.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial...
Can you invest in Gossamer Bio, Inc.?
Yes. Gossamer Bio, Inc. is publicly traded on NASDAQ under the ticker GOSS.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Gossamer Bio, Inc.
Detailed equity research is provided by MarketSnap.